Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Hepatocellular Carcinoma|Pancreatic Ductal Adenocarcinoma|Biliary Tract Cancers|Esophageal Squamous Cell Carcinoma|Triple Negative Breast Cancer|Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer|Head and Neck Squamous-Cell Carcinoma
Interventions: DRUG: ABBV-400
Sponsor: AbbVie